A homegrown vaccine?
Listen now
Description
As results of the first human trials of Oxford University vaccine show immune reaction produced without any serious adverse reactions, virologist Dr Elisabetta Groppelli joins Theodora Louloudis to discuss why she thinks the results are ‘very, very encouraging’, whether a vaccine is ‘one size fits all’ and how virus mutation could affect crucial immunology research.
Read more about the potential coronavirus treatment from Synairgen: https://bit.ly/2WG5Fzr
Read more about Test and Trace privacy allegations: https://bit.ly/2WEPdPS
Read more about French face masks: https://bit.ly/3fMPSq6
For 30 days' free access to The Telegraph: www.telegraph.co.uk/audio
Email: [email protected]
More Episodes
It employs nearly one in ten UK workers, but it’s the industry set to suffer the most when England's new tier system comes into force. CEO of UKHospitality, Kate Nicholls tells Theodora Louloudis why limited evidence of infection in pubs and restaurants means the sector has been wrongly singled...
Published 11/24/20
Published 11/24/20
Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They...
Published 11/19/20
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
